Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308977984> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W4308977984 endingPage "vii53" @default.
- W4308977984 startingPage "vii53" @default.
- W4308977984 abstract "Abstract OBJECTIVES Standard of care for newly diagnosed glioblastoma after resection includes concurrent temozolomide (TMZ) and radiation therapy followed by adjuvant TTF with maintenance TMZ. Preclinical studies suggest TTF and radiotherapy work synergistically. We evaluate the benefit of concurrent TTF with CRT vs adjuvant TTF with TMZ after CRT. METHODS Concurrent TTF with CRT patients were enrolled in a single-arm pilot study (clinicaltrials.gov Identifier: NCT03477110). For the comparison control of adjuvant TTF, adult patients with newly diagnosed GBM that had a KPS ≥ 60 who received treatment with CRT and adjuvant TMZ + TTF from three institutions were included. The adjuvant TTF cohort excluded patients who progressed during CRT or did not receive TMZ. PFS and OS were compared between groups. RESULTS A total of 87 patients were included in this study, of which 30 received concurrent TTF with CRT. Median patient age was 58 in the concurrent TTF group and 59 in the adjuvant TTF group. The median KPS in both groups was. MGMT methylation was present in 33.3% of the concurrent TTF and 32.0% in the adjuvant TTF group. 40% received GTR in the concurrent group and 38% received GTR in the adjuvant group. Multifocal disease was appreciated in 40% of patients in the concurrent TTF group. There was no significant difference in median OS (p=0.38) or PFS (p=0.76). CONCLUSIONS There was no difference in OS or PFS between concurrent or adjuvant TTF treatment groups. However, the adjuvant TTF group is expected to be a better prognosis due to the elimination of patients that progressed or declined after initial CRT. The current study suggested concurrent TTF treatment achieved outcomes to that of a better prognosis group. The survival benefit of concurrent TTF with CRT vs adjuvant TTF is being tested in the phase 3 TRIDENT EF-32 clinical trial (NCT04471844)." @default.
- W4308977984 created "2022-11-20" @default.
- W4308977984 creator A5016198611 @default.
- W4308977984 creator A5018814142 @default.
- W4308977984 creator A5037107652 @default.
- W4308977984 creator A5040932828 @default.
- W4308977984 creator A5059909608 @default.
- W4308977984 creator A5071629337 @default.
- W4308977984 creator A5085091575 @default.
- W4308977984 creator A5086827983 @default.
- W4308977984 date "2022-11-01" @default.
- W4308977984 modified "2023-10-14" @default.
- W4308977984 title "RADT-19. CHEMORADIATION (CRT) TREATMENT WITH OR WITHOUT CONCURRENT TUMOR-TREATING FIELDS (TTFIELDS) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)" @default.
- W4308977984 doi "https://doi.org/10.1093/neuonc/noac209.209" @default.
- W4308977984 hasPublicationYear "2022" @default.
- W4308977984 type Work @default.
- W4308977984 citedByCount "0" @default.
- W4308977984 crossrefType "journal-article" @default.
- W4308977984 hasAuthorship W4308977984A5016198611 @default.
- W4308977984 hasAuthorship W4308977984A5018814142 @default.
- W4308977984 hasAuthorship W4308977984A5037107652 @default.
- W4308977984 hasAuthorship W4308977984A5040932828 @default.
- W4308977984 hasAuthorship W4308977984A5059909608 @default.
- W4308977984 hasAuthorship W4308977984A5071629337 @default.
- W4308977984 hasAuthorship W4308977984A5085091575 @default.
- W4308977984 hasAuthorship W4308977984A5086827983 @default.
- W4308977984 hasBestOaLocation W43089779841 @default.
- W4308977984 hasConcept C126322002 @default.
- W4308977984 hasConcept C143998085 @default.
- W4308977984 hasConcept C2776194525 @default.
- W4308977984 hasConcept C2777389519 @default.
- W4308977984 hasConcept C2777863537 @default.
- W4308977984 hasConcept C502942594 @default.
- W4308977984 hasConcept C509974204 @default.
- W4308977984 hasConcept C71924100 @default.
- W4308977984 hasConcept C72563966 @default.
- W4308977984 hasConceptScore W4308977984C126322002 @default.
- W4308977984 hasConceptScore W4308977984C143998085 @default.
- W4308977984 hasConceptScore W4308977984C2776194525 @default.
- W4308977984 hasConceptScore W4308977984C2777389519 @default.
- W4308977984 hasConceptScore W4308977984C2777863537 @default.
- W4308977984 hasConceptScore W4308977984C502942594 @default.
- W4308977984 hasConceptScore W4308977984C509974204 @default.
- W4308977984 hasConceptScore W4308977984C71924100 @default.
- W4308977984 hasConceptScore W4308977984C72563966 @default.
- W4308977984 hasIssue "Supplement_7" @default.
- W4308977984 hasLocation W43089779841 @default.
- W4308977984 hasOpenAccess W4308977984 @default.
- W4308977984 hasPrimaryLocation W43089779841 @default.
- W4308977984 hasRelatedWork W1991650610 @default.
- W4308977984 hasRelatedWork W2036862336 @default.
- W4308977984 hasRelatedWork W2039289142 @default.
- W4308977984 hasRelatedWork W2107163829 @default.
- W4308977984 hasRelatedWork W2740663609 @default.
- W4308977984 hasRelatedWork W2785997898 @default.
- W4308977984 hasRelatedWork W3174247396 @default.
- W4308977984 hasRelatedWork W4249757522 @default.
- W4308977984 hasRelatedWork W4255330822 @default.
- W4308977984 hasRelatedWork W4316877642 @default.
- W4308977984 hasVolume "24" @default.
- W4308977984 isParatext "false" @default.
- W4308977984 isRetracted "false" @default.
- W4308977984 workType "article" @default.